Tag: ROKU

Blue Horseshoe Stocks: ADIL Update

Adial Pharmaceuticals, Inc. ADIL

It has been an absolutely awful end to 2018, with a market bloodbath beginning roughly six weeks ago and amounting to perhaps the worst conditions we’ve seen in a decade. Despite that fact, with most big-board stock hovering at or near their annual lows, we have still managed to find a few plays that have bucked the trend.

One such stock is ADIL, which we signaled a couple weeks back on the morning of the 13th. That day, the stock was trading for as little as 2.55 a share. It has mainly experienced bullish activity even as everything around it has been going the opposite way. On Monday ADIL reached a new high of 5.75, marking a move of 125% in a span of two weeks.

Aemetis, Inc. AMTX

If you’re searching for a bottom play, you won’t have far to look in this market, as we just mentioned above. However, among all these bottom-feeding stocks we’ve got AMTX, which has a compelling reason to perhaps begin to recover some ground.

This morning, the company announced a huge round of non-toxic funding which is going to allow it to begin implementing a key element of its strategy in the New Year. We’re going to place AMTX on watch into 2019, especially with the company having a conference call scheduled for the second week in January. Things could get interesting between now and then thanks to this morning’s news.

CUPERTINO, CA, Dec. 26, 2018 (GLOBE NEWSWIRE) Aemetis, Inc. (AMTX) announced today that its subsidiary, Aemetis Biogas LLC, closed a $30 million equity investment without any dilute stock issuance by Aemetis, Inc. and funded the first $8.3 million tranche to subsidiary Aemetis Biogas to build, own and operate dairy biomethane digesters, pipelines and gas cleanup/compression facilities primarily under 20-year agreements with dairy farms in California (>>View Full PR)

Extended Watchlist:
ROKU, ESES, GNMK, CTT, MRIN, TRXC, INPX, HSGX

Blue Horseshoe Stocks: Options Review & More

OPTIONS REVIEW

We had two fresh options trading ideas included in yesterday morning premarket report, and it should come as no shock to anyone who has been following our recent activity that we hit the nail on the head with both of them! We signaled some YELP and ROKU Calls, and of the eight sets of contracts we targeted, EIGHT produced big-time, multi-bag, single session gains!

YELP Weekly $43-44.50 Calls

$43 Calls – Range: 1.70-6.46 – Max Gain:  280%
$43.50 Calls – Range: 1.34-5.85 – Max Gain: 337%
$44 Calls – Range: 1.04-5.60 – Max Gain: 438%
$44.50 Calls – Range: .66-5.07 – Max Gain: 668%
________

ROKU Weekly $52-53.50 Calls

$52 Calls– Range: 2.00-5.85 – Max Gain:  193%
$52.50 Calls – Range: 1.50-5.35 – Max Gain: 257%
$53 Calls – Range: 1.36-4.80 – Max Gain: 253%
$53.50 Calls – Range: 1.10-4.40 – Max Gain: 300%
________

Fresh Idea:
OSTK Weekly $44.50-46.50

Extended Watchlist:
SA, IZEA, AWX, PLNT

Blue Horseshoe Stocks: Z Follow-Up & More

Zillow Group, Inc. Z

First thing’s first- we wanted to update our readers once again on the Zillow calls we made on Tuesday morning. We designated the Z Weekly $48-49 Calls as our targets and after a good first day, the stock continued its upward climb during yesterday’s session.

That move alloted for even further increases on our observed range of contracts, and pushed our two-day observed swings well into multi-bag territory:

$48 Calls – Range: 1.30-3.55 – Max Gain: 173%
$48.50 Calls – Range: 1.10-2.60 – Max Gain: 136%
$49 Calls – Range: .80-2.60 – Max Gain: 225%
________

Fresh Ideas:
YELP Weekly $43-44.50 Calls
ROKU Weekly $52-53.50 Calls

Healthmed Services, Inc HEME

It isn’t often these days that we target a subpenny OTC stock. Our long-time followers know that those were our primary focus when we started out exactly 7 years ago this past Tuesday. We did very well in that capacity for many years, despite having recently shifted focus more to fast-paced options trading.

Of any of the sectors we ever covered in the OTC space, cannabis has certainly been the most exciting, and continues to be one of our primary interests on the stock side of things to this day.

That’s why we just want to put HEME on our readers radars. Despite being listed as defunct on OTC Markets, the company recently revealed its intentions to get things back on track and enter the marijuana space.

According to its updated website, HEME is presently acquiring, leasing and licensing growers for the cultivation, production and distribution of cannabis and cannabis-related products in southern California. The project site has state Highway access, water and local transportation are convenient and accessible, and the City government has designated the project site – legal planting zoning.

We are going to keep tabs on the company’s progress toward not only developing in this new direction, but also coming current on its reporting.

Extended Watchlist:
WIN, UPL, TIVO, ANGI, CVNA, RDHL,